French Pharma licenses California PD-1 Cancer Antibody for €710M

13/07/2016 - 2 minutes

San Diego’s Sorrento Therapeutics has bagged a quarter-billion euro deal with Servier. The French Pharma giant will develop Sorrento’s PD-1 targeting platform – a key checkpoint inhibitor in Immuno-Oncology.

Sorrento Biotech ServierSorrento’s proprietary G-MAB library platform was used to identify and generate STI-A1110, an antibody which targets PD-1, one of the key targets in the rapidly developing immuno-oncology therapy market.

In-depth analysis of deep sequencing DNA data showed that the G-MAB library contains more than 10 quadrillion (1016) distinct antibody sequences, which Sorrento claims makes it one of the largest fully human antibody libraries in the industry.

The antibody specialist may therefore receive up to €710 million in various payments, with a non-refundable €25M also being offered as an upfront fee.

Sorrento Servier Cancer PD-1

The idea is to combine Sorrento’s drug with several other of Servier’s portfolio drugs to target hematological and solid tumor cancers, a popular strategy in Immuno-Oncology. In exchange, Servier will obtain worldwide exclusive rights to commercialise and market the resulting therapy.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member